STAT+: Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing Amgen Biotech biotechnology Clinical trials Obesity Pharma Pharmaceuticals STAT+ weight loss STAT+: Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing nounou007 June 23, 2025 CHICAGO — Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side... Read More Read more about STAT+: Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
